Parsatuzumab
- Product NameParsatuzumab
- CAS1312797-14-0
- CBNumberCB68080864
- MW0
- MOL FileMol file
- MSDS FileSDS
Chemical Properties
| form | Liquid |
| color | Colorless to light yellow |
| FDA UNII | 435M4HCP2M |
| NCI Drug Dictionary | parsatuzumab |
Parsatuzumab Price
| Product number | Packaging | Price | Product description | Buy |
|---|---|---|---|---|
| ChemScene CS-0612948 | 1mg | $260 | Parsatuzumab 97.40% |
Buy |
| ChemScene CS-0612948 | 5mg | $677 | Parsatuzumab 97.40% |
Buy |
| ChemScene CS-0612948 | 10mg | $1083 | Parsatuzumab 97.40% |
Buy |
| aablocks AA0294TG | 1mg | $146 | Parsatuzumab |
Buy |
| Arctom HY-P99215 | 1mg | $228 | Parsatuzumab 97.40% |
Buy |
Parsatuzumab Chemical Properties,Usage,Production
Uses
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition[1].in vivo
Parsatuzumab (anti-EGFL7) enhances the antiangiogenesis, tumor growth control, and survival associated with antiVEGF monotherapy in several xenograft and genetically engineered murine tumor models[1].
Parsatuzumab (50 mg/kg; i.v.; 3 times per week) targets EGFL7 and inhibits mantle cell lymphoma (MCL) cell growth and prolongs survival in mouse models of MCL[2].
| Animal Model: | NSG mice injected with Rec1 cells (s.c.)[2] |
| Dosage: | 50 mg/kg |
| Administration: | Intravenous injection; 3 times per week; sacrificed mice when tumor reached end point criteria |
| Result: | Significantly decreased tumor volume than IgG and increased survival of mice. |
References
[1] García-Carbonero R, et al. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. Oncologist. 2017 Apr;22(4):375-e30. DOI:10.1634/theoncologist.2016-0133[2] Chinmayee Goda, et al. Dorrance, Epidermal Growth Factor-like 7 As a Novel Therapeutic Target in Mantle Cell Lymphoma. Blood. 138(S1), 2021:3300.
Preparation Products And Raw materials
Parsatuzumab Suppliers
Global(23)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| 1-631-485-4226; 16314854226 |
info@bocsci.com | United States | 9920 | 65 | |
| 177-54423994 17754423994 |
2853530910@QQ.com | China | 7996 | 62 | |
| 15817493340 | 981810490@qq.com | China | 1577 | 58 | |
| 027-65317797 15926423062 |
422450190@qq.com | China | 10302 | 58 | |
| 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 | |
| 4008200310 15002144251 |
marketing@tsbiochem.com | China | 24951 | 58 | |
| 027-65279366 18108604356 |
products@biolabreagent.com | China | 9864 | 58 | |
| 13720134139 086-15871494362 13720134139 |
orders@jknbiochem.com | China | 7284 | 58 | |
| 021-65675885 18964387627 |
customer_service@efebio.com | China | 11963 | 58 | |
| 027-027-16602739303 16602739303 |
673003916@qq.com | China | 4622 | 58 |
1312797-14-0, ParsatuzumabRelated Search
PROMPT×
PROMPT
The WhatsApp is temporarily not supported in mainland China
The WhatsApp is temporarily not supported in mainland China
Cancel
Determine